JP2022517753A - 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド - Google Patents

脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド Download PDF

Info

Publication number
JP2022517753A
JP2022517753A JP2021539140A JP2021539140A JP2022517753A JP 2022517753 A JP2022517753 A JP 2022517753A JP 2021539140 A JP2021539140 A JP 2021539140A JP 2021539140 A JP2021539140 A JP 2021539140A JP 2022517753 A JP2022517753 A JP 2022517753A
Authority
JP
Japan
Prior art keywords
subject
ligand
pharmaceutical composition
fat
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539140A
Other languages
English (en)
Japanese (ja)
Inventor
ファーブスタイン，モッティ
イツァク，インバル
コーエン，シラ
フィシュマン，プニナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of JP2022517753A publication Critical patent/JP2022517753A/ja
Priority to JP2023078136A priority Critical patent/JP2023100928A/ja
Priority to JP2025049941A priority patent/JP7894175B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021539140A 2019-01-06 2020-01-05 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド Pending JP2022517753A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023078136A JP2023100928A (ja) 2019-01-06 2023-05-10 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2025049941A JP7894175B2 (ja) 2019-01-06 2025-03-25 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes
IL264112 2019-01-06
PCT/IL2020/050011 WO2020141535A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023078136A Division JP2023100928A (ja) 2019-01-06 2023-05-10 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド

Publications (1)

Publication Number Publication Date
JP2022517753A true JP2022517753A (ja) 2022-03-10

Family

ID=65656120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021539140A Pending JP2022517753A (ja) 2019-01-06 2020-01-05 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2023078136A Pending JP2023100928A (ja) 2019-01-06 2023-05-10 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2025049941A Active JP7894175B2 (ja) 2019-01-06 2025-03-25 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023078136A Pending JP2023100928A (ja) 2019-01-06 2023-05-10 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2025049941A Active JP7894175B2 (ja) 2019-01-06 2025-03-25 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド

Country Status (11)

Country Link
US (1) US12213990B2 (enExample)
EP (1) EP3906034A1 (enExample)
JP (3) JP2022517753A (enExample)
KR (1) KR20210113279A (enExample)
CN (1) CN113543790A (enExample)
AU (1) AU2020205042B2 (enExample)
BR (1) BR112021013084A2 (enExample)
CA (1) CA3126002A1 (enExample)
IL (2) IL264112A (enExample)
MX (1) MX2021008172A (enExample)
WO (1) WO2020141535A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300014340A1 (it) * 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물
JP2018534333A (ja) * 2015-11-23 2018-11-22 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
CA2296485A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
WO2012027695A1 (en) * 2010-08-26 2012-03-01 Northeastern University Methods and compositions for preventing or treating obesity
WO2013111132A1 (en) 2012-01-23 2013-08-01 Can-Fite Biopharma Ltd. Treatment of liver conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018534333A (ja) * 2015-11-23 2018-11-22 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
EP3906034A1 (en) 2021-11-10
JP2025098147A (ja) 2025-07-01
IL264112A (en) 2020-07-30
JP2023100928A (ja) 2023-07-19
US20220079968A1 (en) 2022-03-17
AU2020205042A1 (en) 2021-07-15
CN113543790A (zh) 2021-10-22
WO2020141535A1 (en) 2020-07-09
BR112021013084A2 (pt) 2021-09-21
US12213990B2 (en) 2025-02-04
MX2021008172A (es) 2021-08-11
AU2020205042B2 (en) 2024-10-10
IL284463A (en) 2021-08-31
KR20210113279A (ko) 2021-09-15
CA3126002A1 (en) 2020-07-09
JP7894175B2 (ja) 2026-07-23
IL284463B1 (en) 2026-04-01
IL284463B2 (en) 2026-08-01

Similar Documents

Publication Publication Date Title
CA2737077A1 (en) Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
US11291681B2 (en) Method for treating fibrotic liver tissue using Cl-IB-MECA
JP2007517019A (ja) 多発性硬化症の治療方法
JP4642847B2 (ja) シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
JP2025098147A (ja) 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
US20210069227A1 (en) A3 adenosine receptor ligand for managing cytokine release syndrome
HK40062237A (en) A3 adenosine receptor ligand for use for achieving a fat loss effect
JP2005526086A (ja) 癌の治療用のｃｄｋ阻害剤と５−ｆｕの組合せ
JP6140825B2 (ja) 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
US20230048888A1 (en) Use of triazolotriazine derivative in treatment of diseases
HK1261991A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK1261991B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK40011453A (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
JP2023099919A (ja) 進行した転移性がんの治療
BR112015002697B1 (pt) Uso de n6-(3-iodobenzil)-adenosina-5'-n-metiluronamida ou n-(3,4- dicloro-fenil)-2- ciclohexil-1h-imidazo[4,5-c]quinolin-4-amina

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110